Balance Sheet
Cash Flow Statement
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageDebt RatioDebt to EquityEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginInterest Coverage RatioInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on SalesTimes Interest Earned

Northwest Biotherapeutics (NWBO) Debt to Equity (2016 - 2025)

Northwest Biotherapeutics' Debt to Equity history spans 16 years, with the latest figure at -$0.36 for Q4 2025.

  • Quarterly results put Debt to Equity at -$0.36 for Q4 2025, down 133.26% from a year ago — trailing twelve months through Dec 2025 was -$0.36 (down 133.26% YoY), and the annual figure for FY2025 was -$0.36, down 133.26%.
  • Debt to Equity for Q4 2025 was -$0.36 at Northwest Biotherapeutics, down from -$0.16 in the prior quarter.
  • In the past five years, Debt to Equity ranged from a high of -$0.08 in Q1 2025 to a low of -$1.06 in Q4 2021.
  • The 5-year median for Debt to Equity is -$0.34 (2023), against an average of -$0.49.
  • The sharpest move saw Debt to Equity tumbled 665.66% in 2021, then skyrocketed 86.89% in 2022.
  • Year by year, Debt to Equity stood at -$1.06 in 2021, then skyrocketed by 36.51% to -$0.68 in 2022, then surged by 52.17% to -$0.32 in 2023, then surged by 52.14% to -$0.15 in 2024, then plummeted by 133.26% to -$0.36 in 2025.
  • According to Business Quant data, Debt to Equity over the past three periods came in at -$0.36, -$0.16, and -$0.1 for Q4 2025, Q3 2025, and Q2 2025 respectively.